These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12020601)

  • 1. Molecular modelling of the peroxisome proliferator-activated receptor alpha (PPAR alpha) from human, rat and mouse, based on homology with the human PPAR gamma crystal structure.
    Lewis DF; Jacobs MN; Dickins M; Lake BG
    Toxicol In Vitro; 2002 Jun; 16(3):275-80. PubMed ID: 12020601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homology modelling of the nuclear receptors: human oestrogen receptorbeta (hERbeta), the human pregnane-X-receptor (PXR), the Ah receptor (AhR) and the constitutive androstane receptor (CAR) ligand binding domains from the human oestrogen receptor alpha (hERalpha) crystal structure, and the human peroxisome proliferator activated receptor alpha (PPARalpha) ligand binding domain from the human PPARgamma crystal structure.
    Jacobs MN; Dickins M; Lewis DF
    J Steroid Biochem Mol Biol; 2003 Feb; 84(2-3):117-32. PubMed ID: 12710995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of some peroxisome proliferators with the mouse liver peroxisome proliferator-activated receptor (PPAR): a molecular modelling and quantitative structure-activity relationship (QSAR) study.
    Lewis DF; Lake BG
    Xenobiotica; 1993 Jan; 23(1):79-96. PubMed ID: 8387235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the mRNA encoding truncated PPAR alpha does not correlate with hepatic insensitivity to peroxisome proliferators.
    Hanselman JC; Vartanian MA; Koester BP; Gray SA; Essenburg AD; Rea TJ; Bisgaier CL; Pape ME
    Mol Cell Biochem; 2001 Jan; 217(1-2):91-7. PubMed ID: 11269670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of peroxisome proliferator-activated receptor alpha to guinea pig hepatocytes confers increased responsiveness to peroxisome proliferators.
    Macdonald N; Holden PR; Roberts RA
    Cancer Res; 1999 Oct; 59(19):4776-80. PubMed ID: 10519382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma.
    Nolte RT; Wisely GB; Westin S; Cobb JE; Lambert MH; Kurokawa R; Rosenfeld MG; Willson TM; Glass CK; Milburn MV
    Nature; 1998 Sep; 395(6698):137-43. PubMed ID: 9744270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A peroxisome proliferator-activated receptor-alpha (PPARalpha) cDNA cloned from guinea-pig liver encodes a protein with similar properties to the mouse PPARalpha: implications for species differences in responses to peroxisome proliferators.
    Tugwood JD; Holden PR; James NH; Prince RA; Roberts RA
    Arch Toxicol; 1998 Feb; 72(3):169-77. PubMed ID: 9520140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ligand-induced peroxisome proliferator-activated receptor alpha conformational change.
    Dowell P; Peterson VJ; Zabriskie TM; Leid M
    J Biol Chem; 1997 Jan; 272(3):2013-20. PubMed ID: 8999894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptor gamma1 (PPAR-gamma1) as a major PPAR in a tissue in which estrogen induces peroxisome proliferation.
    Ma H; Tam QT; Kolattukudy PE
    FEBS Lett; 1998 Sep; 434(3):394-400. PubMed ID: 9742961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alteration of a single amino acid in peroxisome proliferator-activated receptor-alpha (PPAR alpha) generates a PPAR delta phenotype.
    Takada I; Yu RT; Xu HE; Lambert MH; Montana VG; Kliewer SA; Evans RM; Umesono K
    Mol Endocrinol; 2000 May; 14(5):733-40. PubMed ID: 10809235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peroxisome proliferator activated receptor (PPAR)alpha agonists inhibit hypertrophy of neonatal rat cardiac myocytes.
    Liang F; Wang F; Zhang S; Gardner DG
    Endocrinology; 2003 Sep; 144(9):4187-94. PubMed ID: 12933694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of the peroxisomal beta-oxidation-dependent pathway by peroxisome proliferator-activated receptor alpha and kinases.
    Latruffe N; Cherkaoui Malki M; Nicolas-Frances V; Clemencet MC; Jannin B; Berlot JP
    Biochem Pharmacol; 2000 Oct; 60(8):1027-32. PubMed ID: 11007938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear receptor corepressor-dependent repression of peroxisome-proliferator-activated receptor delta-mediated transactivation.
    Krogsdam AM; Nielsen CA; Neve S; Holst D; Helledie T; Thomsen B; Bendixen C; Mandrup S; Kristiansen K
    Biochem J; 2002 Apr; 363(Pt 1):157-65. PubMed ID: 11903058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peroxisome proliferator-activated receptors: finding the orphan a home.
    Green S; Wahli W
    Mol Cell Endocrinol; 1994 Apr; 100(1-2):149-53. PubMed ID: 8056148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subtype specific effects of peroxisome proliferator-activated receptor ligands on corepressor affinity.
    Stanley TB; Leesnitzer LM; Montana VG; Galardi CM; Lambert MH; Holt JA; Xu HE; Moore LB; Blanchard SG; Stimmel JB
    Biochemistry; 2003 Aug; 42(31):9278-87. PubMed ID: 12899614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 45 kDa protein related to PPARgamma2, induced by peroxisome proliferators, is located in the mitochondrial matrix.
    Casas F; Domenjoud L; Rochard P; Hatier R; Rodier A; Daury L; Bianchi A; Kremarik-Bouillaud P; Becuwe P; Keller J; Schohn H; Wrutniak-Cabello C; Cabello G; Dauça M
    FEBS Lett; 2000 Jul; 478(1-2):4-8. PubMed ID: 10922459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors.
    Xu HE; Lambert MH; Montana VG; Plunket KD; Moore LB; Collins JL; Oplinger JA; Kliewer SA; Gampe RT; McKee DD; Moore JT; Willson TM
    Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13919-24. PubMed ID: 11698662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction between peroxisome proliferator-activated receptor gamma and its agonists: docking study of oximes having 5-benzyl-2,4-thiazolidinedione.
    Iwata Y; Miyamoto S; Takamura M; Yanagisawa H; Kasuya A
    J Mol Graph Model; 2001; 19(6):536-42, 598-600. PubMed ID: 11552681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is peroxisome proliferation an obligatory precursor step in the carcinogenicity of di(2-ethylhexyl)phthalate (DEHP)?
    Melnick RL
    Environ Health Perspect; 2001 May; 109(5):437-42. PubMed ID: 11401753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conserved amino acids in the ligand-binding and tau(i) domains of the peroxisome proliferator-activated receptor alpha are necessary for heterodimerization with RXR.
    Gorla-Bajszczak A; Juge-Aubry C; Pernin A; Burger AG; Meier CA
    Mol Cell Endocrinol; 1999 Jan; 147(1-2):37-47. PubMed ID: 10195690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.